DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Asahi Intecc Partners with Penumbra; Prosoma and EVERSANA Announce Commercialisation Partnership; Zynex Starts Enrollment in the Blood Loss Detection Clinical Trial; Reva Initiates Enrollment in the MOTIV IDE Clinical Trial; FDA Clearance to QT Imaging to Calculate Fibroglandular Volume of the Breast; FDA 510k Clearance to iMediSync’s EEG scanner ‘iSyncWave’ Visit Post
2 What Compelling Applications is Brain-computer Interfacing Bringing to the Healthcare Market? Visit Post
3 Focal Segmental Glomerulosclerosis Market: Unfolding Insights into the Future Visit Post
4 Aerin Medical’s RhinAer Stylus; CE Mark for Haemonetics’s VASCADE Vascular Closure Device; J&J Vision Launches ACUVUE OASYS MAX 1-Day; Olympus Launches VISERA ELITE III Surgical Visualization Platform; GlucoRx’s Non-Invasive Glucose Monitoring Platform; Medtronic-BioIntelliSense’s Partnership; Corindus’s CorPath GRX Neurovascular System Trial; GE & Lantheus [18F]flurpiridaz PET Radiotracer Trial; Pulmonx’s AeriSeal System Trial; AtriAN’s Second Study on Cardioneuroablation Visit Post
5 eCential Robotics’s Surgical Robotic Platform for Spine Surgery; Baxter Gets 510(k) Clearance for Syringe Pump; Medical Microinstruments’s NanoWrist Instruments; Magnus' SAINT Neuromodulation System; Henry Schein Acquires Midway Dental Supply Visit Post
6 How Is Digital Therapeutics Reshaping the Future of Healthcare? Visit Post
7 EMA to review Cidara Therapeutics’ Rezafungin; EU Approves Gilead Sciences’ Sunlenca; FDA Approves Axsome’s Auvelity; EU Marketing Authorisation to Oncopeptides’s Pepaxti; Merck Signs $ 3.5 B Deal with Orna; FDA to review AstraZeneca and Merck’s Lynparza; FDA Approval to Bluebird’s Zynteglo; FDA Decision Date for GSK’s Momelotinib Visit Post
8 AAV Vectors in Gene Therapy: How Recent Clinical Advances are Unraveling New Potentials? Visit Post
9 CereVasc’s eShunt System Study; FDA Approves NGS-Based CDx for Trastuzumab Deruxtecan; Nanopath Secures $10 Million Funding; BD, Accelerate Diagnostics Announce Collaboration; Avails Medical’s Clinical Trials for eQUANT; Movano Ring Exceeds Accuracy Targets for SpO2 & Heart Rate Monitoring Visit Post
10 Rapid Medical’s TIGERTRIEVER 13; Glaukos’s Istent Infinite System; GE Healthcare’s Definium 656 HD; NeuroOne’s Signed Exclusive Development & Distribution Agreement with Zimmer; Kaia Health’s Rise-uP Randomized Controlled Trial; Bluejay’s Symphony IL-6 Test Visit Post
11 How is Telepsychiatry Fulfilling the Evolving Mental Healthcare Demand? Visit Post
12 New Approved PML Treatment Options - A Long-awaited Hope for PML Patients Visit Post
13 How is Artificial Intelligence (AI) Playing a Constructive Role in Mental Health Management? Visit Post
14 AbbVie & iSTAR’S Strategic Alliance; Baxter Launches Welch Allyn RetinaVue 100 Imager PRO; Instylla’S Embrace Hydrogel Embolic System; Primary Endpoint Met in the RADIANCE II US Trial; Roche's Elecsys Amyloid Plasma Panel; EU Approval to Seegene’s Allplex; SARS-CoV-2/FluA/FluB/RSV Assay Visit Post
15 How are Neurostimulation Devices Playing a Vital Role in the Treatment of Chronic Pain? Visit Post
16 VistaGen’s PH94B for Anxiety Disorder; Keytruda for Head and Neck Cancer Treatment; Bavarian Nordic’s Smallpox Vaccine Imvanex; CAMP4 Raises USD 100 Million; Incyte's WU-CART-007; Incyte’s Opzelura for Vitiligo; AstraZeneca and Merck’s Lynparza; Sumitomo Pharma’s DSP-0390 for Brain Cancer Visit Post
17 FDA Approval to Centinel’s Total Disc Replacement Devices; FDA clears DyAnsys' Neurostimulator; Orthox to Commence FFLEX Study; Cordis Started Enrolment for RADIANCY Clinical Study; Orthofix & LimaCorporate Announce Partnership; Medtronic to Partner With AWS Visit Post
18 Byondis’s HER2-targeting ADC trastuzumab duocarmazine; AbbVie Migraine Drug Atogepant; Grünenthal Acquires Bayer’s Testosterone Drug Rights; Vertex Acquires ViaCyte; Merck & Orion Announces Collaboration; Verve Starts Trials of Cholesterol Drug; Kyowa Kirin Drops Nourianz follow-up KW-6356; FDA Orphan Drug and Fast Track Designations to CV-01 Visit Post
19 Zsquare ENT-Flex Rhinolaryngoscope Receives FDA Clearance; ClearMind Biomedical's Completion of Least Invasive ICH Treatment; Bruker Launched Tool for ‘Long COVID’ Multi-Organ Risk Assessment; EarlySign, Roche Signed Strategic Deal; FDA Clearance for Leva® Pelvic Health System; NeuroOne’s Evo® sEEG Electrode Visit Post
20 Role of Seizures Alert and Monitoring Devices in the Management of Epilepsy Visit Post
21 Novo Nordisk’s Concizumab for Hemophilia; AbbVie Ends its Alliance with Alector; ADC Therapeutics and Sobi Enters in Exclusive Licensing Deal; BMS’ Opdivo Gets NHS Use; Merck to Acquire Seagen; FDA Priority Review to Roche’s Lunsumio; AstraZeneca to Acquire TeneoTwo; FDA Orphan Drug Designation to PBI-200 Visit Post
22 Ipsen to Buy Epizyme; BioMarin's Gene Therapy for Hemophilia; AbbVie's Qulipta for Chronic Migraine; FDA Approves Breyanzi for R/R LBCL; NDA Filed for Elacestrant in ER+/HER2- Breast Cancer; EU Approval to Enhertu for Breast Cancer; FDA Approves Novartis’ BRAF-positive Tumor Combination; GSK’s Hepatitis B Vaccine, Bepirovirsen Visit Post
23 Will a Robust Pipeline Address the Major Depressive Disorder Treatment Conundrum? Visit Post
24 How is Nanomedicine Transforming the Dynamics of the Healthcare Industry? Visit Post
25 Biogen terminates ALS Pact with Karyopharm; AbbVie’s Immunological Drug Skyrizi; NICE Backs Astellas’ Oral Therapy Evrenzo; Roche’s Crenezumab Fails in Clinical Trial; FDA Grants Fast Track Designation to Dianhydrogalactitol; Sierra Oncology Submits NDA for Momelotinib Visit Post
26 Role of Digital Therapeutics (DTx) in Mental Health Management Visit Post
27 GSK’s RSV Vaccine Clears Phase III Test in Adults; Roche’s Tecentriq for Adjuvant NSCLC; Owkin Bags $ 180 million from BMS; EU Approves Roche’s Mosunetuzumab; Dostarlimab Elicits Clinical Complete Response in dMMR Rectal Cancer; FDA Backs Bluebird’s CALD Gene Therapy; Takeda’s Dengue Fever Vaccine TAK-003; FDA Approves Dupilumab Visit Post
28 CG Oncology Teams Up With Merck & BMS; Parse Biosciences Partners With Molecular Diagnostics Korea; Amgen's Olpasiran; Elevar Therapeutics Announces Results of Rivoceranib; FDA Approves GSK’s Measles Vaccine; Sage & Biogen Reveals Postpartum Depression Trial Result Visit Post
29 Epidiolex vs Fintepla: Fight in Rare Epilepsies Visit Post
30 PTC Therapeutics’ Gene Therapy Upstaza; Sanofi and Regeneron’s Dupixent; Bayer CAR-T Collaboration with Atara; FDA Accepts Biohaven’s Zavegepant; AbbVie Files FDA Approval for ABBV-951; Innoviva to Acquire Entasis; FDA Orphan Drug Designation to XMT-2056; FDA Approves Azacitidine for Juvenile Myelomonocytic Leukemia Visit Post
31 Check-Cap’s Pivotal Trial for C-Scan; Curebase and Flow Neuroscience’s tDCS Device; Brainlab Acquires Majority Share in medPhoton; GE Healthcare to Invest in Pulsenmore; Medtronic’s Drug-Eluting Coronary Stent System; Remedee’ Endorphin Stimulation Solution; Visit Post
32 BMS Sells NY Biologics Plant; FDA Approves Mitsubishi Tanabe’s Radicava, Love Pharma Acquires MicroDoz; Sandoz Launches Generic of Roche's Esbriet; Pfizer to Acquire Biohaven Pharma; eureKARE’s Cell and Gene Therapy CDMO; Atamyo’s LGMD Gene Therapies; FDA approves Eli Lilly's Type 2 Diabetes Treatment Visit Post
33 Abbott’s Alinity m STI Assay; Phillips’ MR 7700 System; HOYA’s MiYOSMART Spectacle Lens; Magneto’s Pulmonary Embolism Treatment; Owen Mumford and Stevanto Group’s Collaboration Deal; Elekta’s Radiosurgery System-Elekta Esprit Visit Post
34 Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases Visit Post
35 Which Pharma Companies are going to Transform the Post Traumatic Stress Disorder Treatment Market? Visit Post
36 VBL Therapeutics’ VB-111 (ofranergene obadenovec); BMS’s mavacamten (Camzyos); Merck’s KEYTRUDA; AstraZeneca and Daiichi’s Enhertu; Pfizer/Biohaven’s VYDURA (rimegepant); AstraZeneca’s Ultomiris; Supernus’s Viloxazine (Qlebree); AbbVie’s Rinvoq Visit Post
37 Emerging Market for Organ on a Chip Visit Post
38 Coherus Biosciences’ Toripalimab; Keymed’s CMG901; Biogen Alzheimer’s Drug Aduhelm; Vicore’s Digital Therapeutics Study; Cassiopea’s Acne Treatment Winlevi; Samsung Biologics Acquires Samsung Bioepis; Roche’s Giredestrant; Ashai Kasei Acquires Bionova Visit Post
39 Rise In Bispecific Antibodies Utilization As Antibody Therapeutics Visit Post
40 Penumbra’s Indigo System; Axonics’s F15 Recharge-free SNS; Stimwave’s FREEDOM-1 Clinical Trial; Virtual Incision’s MIRA Platform; SonoScape’s HD-550 Endoscopy system; SMART Medical’s G-EYE Colonoscope Series Visit Post
41 How Metaverse is Set to Transform the Healthcare Dynamics? Visit Post
42 BioXcel’s Agitation Drug Igalmi; FDA Approves Cysteine Hydrochloride Injection; Gilead’s Trodelvy; Alembic Pharma’s Topical Anesthetic Cream; Pfizer Acquires ReViral; Telix Buys Lilly's Failed Cancer Drug Lartruvo Visit Post
43 Precigen's PRGN-3006; Yescarta Approved as a First CAR T-cell Therapy for R/R LBCL; Biogen & Ionis’ BIIB078; Nobelpharma's HYFTOR (sirolimus topical gel) 0.2%; Cerevance Parkinson’s Drug; Sanofi & Regeneron’s Dupixent; Clovis’s Rubraca for Ovarian Cancer; Immunocore Eye Cancer Cell Therapy Approval Visit Post
44 Ypsomed-CamDiab's Collaboration; Vela Diagnostics’s NGS-Based Pan-Cancer Panels; Fresenius's SMOFlipid Lipid Injectable Emulsion; Sientra Gained Regulatory Nod to Market Breast Implants; Synchron’s Endovascular BCI Stentrode Device; HLT’s TAVR Clinical Studies Visit Post
45 Sanofi’s Rare Disease Drug Xenpozyme' Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB's FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval Visit Post
46 Smithfield BioScience and BioCircuit’s Nerve Tape Device; Cynosure-Jeisys Medical’s Partnership; bioMérieux’s VITEK® MS PRIME new MALDI-TOF Mass Spectrometry Identification System; Artio Medical’s Gold Embolization Device; Heartpoint Global's Implant System; ObvioHealth’s Virtual Urogynecology Clinical Trial Visit Post
47 Bristol Myers’ Opdivo combo Opdualag for Melanoma; Biogen’s Aduhelm; Marinus’ Ztalmy for CDKL-5 Deficiency Disorder; Merck’s Keytruda + Lynparza; Vitaris’s Breyna; Moderna’s Second COVID-19 Booster Shot; Takeda’s Exkivity; BMS’s First LAG-3 Checkpoint Inhibitor Visit Post
48 NeuroLogica’s OmniTom Elite; Cordis’s S.M.A.R.T. RADIANZ Vascular Stent System; Rockley Photonics and Medtronic’s Collaboration; NovaSight’s Amblyopia Treatment Device; Cardiawave’s VALVOSOFT; OSF Ventures invests in wireless seizure detection sensor Visit Post
49 Can Cannabinoids be an Effective Medicinal Substance? Visit Post
50 AstraZeneca and Merck’s Lynparza; Venatorx’s cefepime-taniborbactam; AbbVie’s Qulipta; AstraZeneca’s IL-5 inhibitor Fasenra; Sandoz Acquires Coalesce; Incyte’s Opxelura; Bayer’s Nubeqa; NICE Rejects Keytruda Plus Chemotherapy Visit Post
51 Most Prominent Players in Nerve Repair and Regeneration Market Visit Post
52 Bioventus’s StimRouter Pain Management Device; FDA Approval for eCoin Therapy; SurGenTec Launches ION Screw; Exactech’s Humeral Reconstruction Prosthesis; Boston Scientific’s WATCHMAN FLX LAAC Device; PathMaker Neuro’s MyoRegulator Visit Post
53 Amyotrophic Lateral Sclerosis Treatment: The Journey of Radicava and Highlights of Riluzole Formulations Visit Post
54 Noninvasix’s LIVOx™ Central Venous Oxygenation Monitor; LivaNova’s aura6000 System; Oxford BioDynamics’s EpiSwitch® CiRT; Masimo’s SedLine® Brain Function Monitoring and the SedLine Pediatric EEG Sensor; Medtronic’s NuVent™ Eustachian Tube Dilation Balloon; Conformis’s published data for Bilateral Knee Implant Study Visit Post
55 Most Promising Therapies in the Parkinson’s Disease Treatment Market Visit Post
56 Össur Launches POWER KNEE; DePuy Synthes Acquires CrossRoads Extremity Systems; Myomo’s MyoPro; Accuray’s TomoTherapy System; Theradaptive’s Spinal Fusion Implant; Senseonics’s Eversense E3 CGM System Visit Post
57 Mapping the Biggest Pharmaceutical Companies by Continents Visit Post
58 Biogen's Aduhelm; FDA Approves Sanofi's Enjaymo; NHS & Orchard Signs a Deal; Bristol’s Breyanzi & Abecma; Pharming’s Leniolisib; Eli Lilly’s Verzenio Trial; UCB’ Zilucoplan Trials Result; Eli Lilly’s Alzheimer's Drug Donanemab Visit Post
59 Merck’s Gefapixant; Pfizer's Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead's Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent Visit Post
60 Suneva Medical-Viveon Health merger update; Smith+Nephew acquires Engage Surgical; Abiomed's preCARDIA technology; Medtronic’s DTM Spinal Cord Stimulation; Endo Tools Therapeutics’s Endomina System; Diadem's AlzoSure predict prognostic blood test Visit Post
61 Algernon’s NP-120 (ifenprodil); Pieris's cinrebafusp alfa (PRS-343) clinical trial; Gaumard Scientific’s multidisciplinary patient simulator HAL S5301; Hekka Labs’s decentralized healthcare ecosystem Visit Post
62 Noxxon’s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent’s clinical trails for NVL-520; Stryker acquires Vocera Communications Visit Post
63 Biogen-Eisai's Aduhelm; Quidel acquires Ortho Clinical Diagnostics; Accutar Biotechnology’s AC0176; Boehringer’s Spesolimab Visit Post
64 Boston Scientific's MODULAR CRM System; Restore Medical's ContraBand clinical trial result; BD acquires Venclose; Roche differentiates mutations in Omicron; Linus's StrandDx-ASD; HelioLiver launches liquid biopsy test Visit Post
65 Aslan Pharma - IQVIA collaboration; Reata's kidney drug bardoxolone; Alzheimer’s Disease treatment update; Recordati to acquire EUSA Visit Post
66 Neuromodulation Devices Observed to Reshape the Migraine Treatment Dynamics Visit Post
67 Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Heptares; FDA opens clearances for hepatitis C diagnostics; Twist nabs antibody discovery biotech Abveris for $190M Visit Post
68 Abbott's Pacemaker System; Ivantis’s Hydrus Microstent; Medtronic’s PillCam Small Bowel 3; ALung Technologies's Hemolung; AppliedVR’s EaseVRx; J&J to split into two companies; OrthAlign’s Lantern® launch; LumiThera’s Light-based Theranostic Visit Post
69 TecTraum’s pro2cool receives Breakthrough Device Designation; Vektor Obtains FDA Clearance for vMap; Medtronic’s TMVR system; Sight Sciences's PRECISION Trial; Alcon to buy Ivantis; Philips to acquire Cardiologs Visit Post
70 Smith+Nephew's LEGION CONCELOC; Renew Bioscience's Cerezen; Perimeter Medical's ATLAS AI Project; SAGA Diagnostics-AZ's Deal; Magnus Receives Breakthrough Device Designation; ReValve's Transeptal Mitral Valve Replacement Visit Post
71 Magnus Medical’s tech gets breakthrough status; Prolacta develops tests for pathogens detection; Renovia gets breakthrough designation for leva system; Hinge Health secures $600M funding Visit Post
72 An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of 2021 (H1) Visit Post
73 Ocular Therapeutix’s insert fails in phase 2; Click Therapeutics raises $52M funding; Roche introduces AVENIO Tumour Tissue CGP Kit; Blue Wolf Capital to acquire CIVCO Radiotherapy Visit Post
74 Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies Visit Post
75 Biogen's ALS drug Tofersen (BIIB067); Phathom's erosive esophagitis drug trial; Vertex's islet cell therapy; Natera launches lung DNA test Visit Post
76 Brickell to Submit New Drug Application to FDA; Twin Health Raises $140M; BMS' Deucravacitinib; Lando Biopharma’s LABP-104 gets Approval; NIH Grant of $ 3 M to Amydis; FDA Grant to GenSight’ GS030 Visit Post
77 Evaluating the Role of Digital Therapeutics as an Alternative to Conventional Therapies for Depression Visit Post
78 Amber Implants VCFix spinal system; iotaMotion's iotaSOFT Insertion System; Boston Scientific acquires Baylis; ReCor's Paradise Ultrasound Renal Denervation; Boston Scientific's Ranger Drug-Coated Balloon; Natera's Prospera Visit Post
79 Exploring the Market Potential of the Upcoming Therapies for the Myasthenia Gravis Visit Post
80 RETINA-AI Health declares positive results; Medtronic's Hugo robotic-assisted surgery system; Boston Scientific acquires Devoro Medical; Paige obtains first-ever FDA approval Visit Post
81 UNION Therapeutics-Innovent's collaboration; Delix Therapeutics bags $ 70 M; Biohaven’s Verdiperstat clinical trial result; Intra-Cellular's CAPLYTA Phase III study Visit Post
82 Scrutinizing the West Syndrome Market Space from Growth Perspectives Visit Post
83 FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises Visit Post
84 Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm Visit Post
85 Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthritis Programme; JandJ's HIV Vaccine Trial; Versanis Bio $70 M Series A Financing; AC Immune's Alzheimer's Antibody Drug Visit Post
86 Charcot-Marie-Tooth Disease Market Size Expects Growth Owing to Increasing Prevalence, Influx of Pharma Companies and Novel Therapies Visit Post
87 Ascendis's SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin's Voxzogo; Zimmer-Canary's Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Visit Post
88 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
89 Von Hippel-Lindau Market Space Expected to Expand at a CAGR 8.3% by 2030 Owing to Increasing Prevalence and Emerging Therapies Visit Post
90 Major Depressive Disorder Market Quadrant Growth Soars Owing to Expected Launch of Key Therapies Visit Post
91 Mounting Prevalence of Neurological Disorders and the Key Companies Bidding to Solve the Riddle Visit Post
92 Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial Visit Post
93 The New Buzz of Transcranial Stimulation Devices in the Neurological Disorders Market Visit Post
94 BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M Visit Post
95 Hepion aces mid-stage study; Bicycle Therapeutics-Ionis collaboration; Nimbus raises $105M; Regeneron to support ISA Pharma Visit Post
96 Neurovascular Thrombectomy Devices Market Visit Post
97 Vagus Nerve Stimulators Market Outlook Visit Post
98 Wearable Devices: Weighing the Potential Benefits and Pitfalls of the Innovative Wearable Products Visit Post
99 Insilico Medicine raises $255M; Sanofi & Translate Bio initiate trial; Medtronic gains expanded FDA approval; Blackstone, Cellex & Intellia form CAR-T startup Visit Post
100 Does the use of Assistive Technologies in Autism Spectrum Disorder Payoff? Visit Post
101 Horizon/ Arrowhead Deal; Dr Reddy's Lab’s Drug US Launch; Targovax’s ONCOS-102; RedHill's Oral Opaganib in COVID-19 Visit Post
102 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
103 Eclipse, Medtronic, Aethlon, Cognoa, ObvioHealth, and others Continue to Veer MedTech Market Forward Visit Post
104 Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation Visit Post
105 Spinal Stenosis Devices Market Size to Balloon Up Owing to Increasing Prevalence & Geriatric Population, as well as Medical Advancements Visit Post
106 Biogen’s Alzheimer’s Drug; FDA approval to Novo Nordisk’s Wegovy; Bluebird's Gene Therapy Visit Post
107 Global Chronic Pain Associated With Painful Diabetic Neuropathy Market Landscape Visit Post
108 Pfizer hit by DMD delay & halts BCMA trials; Sarepta's drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic Visit Post
109 MedTech Industry Roars Back as FDA Approvals Soar Visit Post
110 Drug Development and Pipeline Analysis in the Alzheimer’s Disease Market Space Visit Post
111 Sleep Disorders: An Emerging Public Health Issue Visit Post
112 Kinase Inhibitors: Challenging the established Biologics as the new standard of care in autoimmune diseases? Visit Post
113 Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels Visit Post
114 How Depression Is Eroding The Mental And The Physical Health Of The Society? Visit Post
115 Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer's Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing Visit Post
116 Ever-Evolving Market Landscape of Transcatheter Aortic Valve Replacement Visit Post
117 How Will New Discoveries of Deep Brain Stimulation Devices Transform the Pharma Domain? Visit Post
118 Asher Bio raises $55M; Roche halts Huntington's phase 3 trial; Novartis' radioligand hits goal in phase 3; EpimAb raises $120M in Series C Visit Post
119 Emerging Therapies in the Chronic Pain Pipeline Transforming the Chronic Pain Market Landscape Visit Post
120 Valo Health receives $110M Series B Cognito's therapy slows Alzheimer's disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio Visit Post
121 Fake News In The Healthcare Sector: A Misinformation Crisis In The Era Of Digitalization Visit Post
122 Eating Disorders: What Happens When Stigma And Misconceptions Command The Health Visit Post
123 The Burden And The Impact Of Mental Health Issues In Today’s Time Visit Post
124 Biohaven's Troriluzole Failure; Daiichi/ AZ's Enhertu; Fujifilm & Manufacturing Spree; J&J's Darzalex Faspro Visit Post
125 The Obesity Pandemic: What can we do about it? Visit Post
126 Parkinson's Disease: How close are we to a cure? Visit Post
127 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
128 Watch Out For Top Pipeline Therapies Making An Impact In The Bipolar Depression Market Visit Post
129 Top 10 Most Promising Drugs In The Amyotrophic Lateral Sclerosis Treatment Landscape Visit Post
130 21 of the most common questions about Epilepsy Visit Post
131 Treating Patients with Software: Digital Therapeutics Visit Post
132 AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra's X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3 Visit Post
133 KaliVir, Astellas licensing deal; AbCellera's IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH Visit Post
134 Advancements in Neuromodulation Visit Post
135 Albireo Pharma's PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna's Weapon Against COVID; Gilead & Novo Nordisk's Cocktail Therapy for NASH Visit Post
136 Ever-evolving Market Dynamics of Epilepsy – a silver lining! Visit Post
137 Fosun-BioNTech's COVID-19 vaccine; Multiple Sclerosis research update; Vosoritide nabs FDA review; FDA nods to paclitaxel-coated Ranger balloon for PAD Visit Post
138 The Growing Burden Of Neurodegenerative Disorders Visit Post
139 Cyclerion's olinciguat flunks sickle cell test; Nimbus nets $60M; Dyno-Roche's gene therapy pact; RayzeBio debuts with $ 45M to target tumors Visit Post
140 Key Pharma Players Changing The Dynamics Of Schizophrenia Market Visit Post
141 Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma Visit Post
142 How do we curb the Opioid Epidemic? Visit Post
143 Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing Visit Post
144 J&J 's COVID-19 vaccine; Roche, AC Immune's anti-Tau Alzheimer's drug; Silverback nets $85 M; Anokion's deal rides out BMS-Celgene merger; Coronavirus spike protein could inspire vaccine development Visit Post
145 Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome's Buyout; Abbott’s MitraClip4 EU Approval; Grail Buybacks Visit Post
146 Roadblocks In The Peripheral Nerve Injury Market Require A Multi-faceted Approach Visit Post
147 The State of Alternative Medicine In The Healthcare Visit Post
148 Amylyx's neuron-protecting drug slows ALS decline; Antisense drugs could help fight ALS and dementia; CAR-T research updates; Orca and Lyell announces research partnership Visit Post
149 Healthcare Delivery System: What lies in the future? Visit Post
150 The Rarity Of Dravet Syndrome: Challenges, and Treatments Visit Post
151 Novartis’s Spartalizumab Combo Stumbles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis Visit Post
152 FDA rejects BioMarin's Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Visit Post
153 Sanofi acquires Principia; FDA's Nod to Roche's Enspryng; BMS, Dragonfly's Licensing Deal Visit Post
154 Gilead's remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche's cancer drug Visit Post
155 FDA's Ok to Roche's Oral SMA Therapy; Roche's Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem Visit Post
156 Medical Marijuana: Is it a blessing in disguise or a curse for humanity? Visit Post
157 Recognising The Warning Signs Of ADHD Visit Post
158 MorphoSys, Incyte receive FDA Ok for Monjuvi; Siemens Healthineers set to buy Varian; Immunic's IMU-838 promising results Visit Post
159 Roche-UCB's $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures Visit Post
160 Addressing The Scattered Harbingers of Frontotemporal Dementia Visit Post
161 Amylyx Raises $30M; QurAlis Announces License Agreement Deal With Lilly; COVID-19 Vaccine Updates; Researchers Develop a New Ultrafast Insulin Visit Post
162 Regeneron's I-O Drug; Gene Therapy for Parkinson's Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M Visit Post
163 Can Alzheimer's be cured with Marijuana? Visit Post
164 Paradigm Shift In The Diabetic Peripheral Neuropathy Market Landscape As The Focus Shifts Towards The Cure Visit Post
165 The Question That Remains Unanswered: What Might Be Causing Alzheimer’s? Visit Post
166 How are Diabetic Peripheral Neuropathy medications changing the DPN market scenario? Visit Post
167 Can Aducanumab Solve the Puzzle Of Alzheimer’s? Visit Post
168 When Technological Innovations Help in Remembering for People Living with Alzheimer’s Visit Post
169 Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M; Visit Post
170 What are the 10 early signs of Alzheimer’s that are overlooked? Visit Post
171 An Ageing Population and Upcoming Therapies: What is shaping the Alzheimer’s Disease Market Scenario? Visit Post
172 Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost Visit Post
173 CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice Visit Post
174 Is the cure for Huntington’s disease on the horizon? Visit Post
175 Acquisition of Stemline; Roche’s Elecsys Anti-SARS-CoV-2 antibody test; Newron’s abandonment of STARS trial Visit Post
176 Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials Visit Post
177 AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes Visit Post
178 Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVID-19 trial Visit Post
179 Dubai: A leading and exciting pharma hotspot Visit Post
180 Gene therapy might make cocaine less addictive Visit Post
181 Opioid Withdrawal Syndrome Pipeline: What lies in the future for those facing withdrawal symptoms Visit Post
182 US approval to Lundbeck’s Vyepti for preventive migraine care; Esperion’s cholesterol-lowering drug Nexletol receives FDA nod; Karius – a start-up company – raises USD 165 Million – strengthens it liquid biopsy testing Visit Post
183 Opioid Withdrawal Syndrome: What happens when a person withdraws from Opiates Visit Post
184 Immune cells for age-related diseases; Regeneron's antibody for 2019-nCoV; FDA nods for hydrogel injection Visit Post
185 Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey Visit Post
186 Potential of Digital therapeutics and increasing CVDs Visit Post
187 Acceleron Pharma's drug sotatercept touches the phase 2 mark; GT Medical receives nod for GammaTile; New treatment strategy for Parkinson's disease Visit Post
188 Tepezza receives approval; a new way to treat Alzheimer’s Visit Post
189 Eli Lilly to acquire Dermira, Boehringer buys Enleofen’s IL-11 platform, Biogen acquires Pfizer’s Alzheimer’s drug Visit Post
190 Marijuana as a treatment approach Visit Post
191 Nunaps raises USD 4.2M; Arcutis files for USD 100M IPO Visit Post
192 Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy Visit Post
193 Schizophrenia vs Bipolar disorder: Biomarkers to the rescue Visit Post
194 Increasing cases of Mania and Bipolar disorder market Visit Post
195 Fragile X Syndrome Market Visit Post
196 Alzheimer's Disease Market Infographic Visit Post
197 Toujeo to treat Type 1 Diabetes; TauRx for Alzheimer’s patients Visit Post
198 Novartis buys Medicines Co. for USD 9.7 Billion Visit Post
199 Complex Regional Pain Syndrome Upcoming Therapies Visit Post
200 Batten Disease Market: Barriers and Growth Opportunities Visit Post
201 GNA Biosolutions raises USD 13.5M; AC Immune collaborates with Penn; Jazz Pharmaceuticals acquires Cavion; Ascletis opens a new Shanghai clinical research centre Visit Post
202 NMPA approves ALS treatment Edavarone; GSK ends development of Ebola vaccines; Vesselon Acquires FDA-Approved Imagent Visit Post
203 CHPM’s positive approval for 13 Medicines; NICE approval for AstraZeneca’s Olaparib; Exact Sciences to buy Genomic Health Visit Post
204 FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia Visit Post
205 Chronic Lower Back Pain Market Analysis Visit Post
206 Chronic Lower Back Pain Therapy Market Visit Post
207 Chronic Lower Back Pain Visit Post
208 EMDR Therapy- Is it really that good? Visit Post
209 Notizia Visit Post
210 What is the link between Alzheimer's and Menopause? Visit Post
211 Lilly overtakes rivals with its Cluster Headache approval Visit Post
212 Antihypertensive drugs decrease Dementia rate Visit Post
213 World Multiple Sclerosis Day Visit Post
214 What is causing a rise in Autism rate? Visit Post
215 The Business Cocktail Visit Post
216 Autism Spectrum Disorder Visit Post
217 Beta Interferons prolongs life in Multiple Sclerosis Visit Post
218 Notizia Visit Post
219 What can be the scope of Medical Marijuana? Visit Post
220 Notizia Visit Post
221 Boys are more likely to have autism! Visit Post
222 The Business Cocktail Visit Post
223 Alzheimer's drug fails! Is it time to move on? Visit Post
224 World Epilepsy Day Visit Post
225 EPILEPSY- A Neurological Disorder Visit Post
226 Complex regional pain syndrome (CRPS)-A debilitating disease Visit Post
227 Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways Visit Post
228 Relation between gut microbes and depression bolstered Visit Post
229 Myasthenia Gravis Visit Post
230 Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal Visit Post
231 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
232 Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod Visit Post
233 Machine Learning Models to Help Predicting Cancer Symptoms, Plan Treatment Visit Post
234 Vedanta raises; Relay Therapeutics reels in; Gene therapy for SMA Visit Post
235 ‘Transmissible’ Alzheimer’s theory gains traction Visit Post
236 Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal Visit Post
237 HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer’s; Bristol-Myers, H3 Biomedicine discover RNA splicing Visit Post
238 Lilly remunerates AC Immune; Akero adds $70M; Ra Pharma $100M Visit Post
239 Notizia Visit Post
240 Roche signs Icagen; UCB devote $255M; Siemens Healthineers celebrates Visit Post
241 Does coconut oil help prevent dementia? Visit Post
242 Notizia Visit Post
243 ‘Invisible’ mice reveal anatomical secrets Visit Post
244 FDA approves Zulresso; Pfizer receives approval; Novartis relinquishes Rituxan Visit Post
245 Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives Visit Post
246 COMMERCIAL AND OTHERS Visit Post
247 KEY CLINICAL OUTCOMES Visit Post
248 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
249 Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune Visit Post
250 Notizia Visit Post
251 Snippet Visit Post
252 Digital Pill: A new frontier in digital healthcare all set to take-off Visit Post
253 Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts Visit Post
254 Voltage-Dependent T-Type Calcium Channel Blockers  Visit Post
255 Regulatory Visit Post
256 Snippet : Migraine Visit Post
257 Snippets : Parkinson Visit Post
258 Commercial Outcomes - Novartis Visit Post
259 Key Clinical Outcomes- 30/07/2018 Visit Post
260 Neuroscience Highlights - 17/07/2018 Visit Post
261 Notizia Visit Post
262 Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential Visit Post
263 Hepatic Encephalopathy- An ailment of liver to brain Visit Post
264 Idera's drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates Visit Post
265 Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation Visit Post
266 Parkinson's and tuberculosis shares a common protein that could provide better drugs for both Visit Post
267 Business Cocktail Visit Post
268 Takeda buys Shire in a deal worth USD 62 billion Visit Post
269 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
270 Horizon Discovery declines Abcam’s USD 367 million takeover bid Visit Post
271 Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment Visit Post
272 Hepatic Encephalopathy- Lack of active pipeline products Visit Post
273 Takeda acquisition on Shire raises its share by 25 percent Visit Post
274 Business Cocktail Visit Post
275 Business Cocktail Visit Post
276 NOTIZIA Visit Post
277 Symdeko’s approval; Erytech target solid tumors; Oncologie snapped bavituximab; Merck delivers Visit Post
278 Spasticity Visit Post
279 Snippet Visit Post
280 NOTIZIA Visit Post
281 KINECT 4 Study; KindredBio Announces Results; Mylan and Aspen’s Launch; EMA investigates; Amgen’s Repatha Visit Post
282 Business Cocktail Visit Post
283 Alzeimer’s drug; Guardant Health receives approval; First Patient Dosed in Phase 1 Clinical Trial; Sunny Pharmtech and Vitruvias Therapeutics Receive FDA Approval Visit Post
284 Thrombolytic Sciences’ trial; NurOwn for ALS; Biosimilar receives approval; Trelegy Ellipta for the treatment of COPD Visit Post
285 Amyotrophic Lateral Sclerosis (ALS) a fatal disease! Visit Post
286 Business CockTail Visit Post
287 Cannabidiol trial; MyoKardia aims; LDL drug data Visit Post
288 Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project Visit Post
289 Progressive Supranuclear Palsy– A neurodegenerative disorder Visit Post
290 Dengvaxia study; Opdivo racks up; FDA issues plant; Teva's Rimsa fraud; Mission bags Fox grant Visit Post
291 Biogen triumphs; Lilly, Pfizer, Ipsen back; Court nixes; Mylan EpiPen recall Visit Post
292 Narcolepsy: Treatment options and market outlook Visit Post
293 Mylan closing Illinois plant; Insys spends $24M; Roche's Ocrevus; Greece’s corruption prosecutor quits Visit Post
294 Pfizer faces patent loss; Allergan over generics probe; Sun Pharma rallies Visit Post
295 SEC scrutinizes; Acacia meets endpoint; Axovant's dementia drug; Novartis expands; Aurobindo responds Visit Post
296 FDA approves; Sun Pharma Recalls; Mezzion filed; Sanofi’s antibody to treat Visit Post
297 Can the brain detect Addictive cravings even after death? Visit Post
298 CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective Visit Post
299 Obsessive-Compulsive Disorder: Emerging Therapies Visit Post
300 Boston Biomedical starts phase III; Martindale receives approval; Merck snagged yes; Nanotechnology to improve HIV Visit Post
301 FDA Approves STELARA; Novartis announces AMG 334; AbbVie's HCV Regimen; PaizaBio Gains CFDA Approval; WuXi Biologics completes construction Visit Post
302 FDA grants approval; Sanaria receives fast-track designation; Sanofi and Regeneron’s next blockbuster; Allele receives NIH grant Visit Post
303 Nav1.7 Blockers- New Genre of Pain Relief Therapy Visit Post
304 Spinal Muscular Atrophy Emerging therapies Visit Post
305 Gene Therapy’s Emergence: The “New” approach for Huntington’s disease Visit Post